CSBio CSBio

X
[{"orgOrder":0,"company":"Affiris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AFFiRiS Announces FDA Response to its pre-IND Submission for Phase 2 trial with AFFITOPE PD01 in Early Parkinson\\'s Disease Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"AUSTRIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Affiris"},{"orgOrder":0,"company":"Affiris","sponsor":"AC Immune","pharmaFlowCategory":"D","amount":"$100.8 million","upfrontCash":"$5.0 million","newsHeadline":"AC Immune Acquires AFFiRiS\u2019 Specific Active Immunotherapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"AUSTRIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Affiris"}]

Find Neurology Drugs in Phase I Clinical Development in AUSTRIA

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            AC Immune is acquiring AFFiRiS’ anti-alpha-synuclein programs (PD01) targeting neurodegenerative diseases caused by misfolded forms of human self-proteins. All acquired programs are based on AFFiRiS´ AFFITOME® technology.

            Lead Product(s): PD01

            Therapeutic Area: Neurology Product Name: PD01

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: AC Immune

            Deal Size: $100.8 million Upfront Cash: $5.0 million

            Deal Type: Acquisition July 27, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            In its written response, the FDA addressed AFFiRiS' questions and provided guidance on the design of the planned phase 2 trial.

            Lead Product(s): PD01

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 27, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY